It led to the development of a different class of substrate-competitive inhibitors that preferentially bind the PRMT5:MEP50 complex with MTA and may be used to pharmacologically exploit the PRMT5-related vulnerability in MTAP−/− cancer cells. This evidence concerns the gene PRMT5 and cancer.